Chemotherapy‑induced Neutropenia after Initial and Subsequent Chemotherapy Cycle of Non‑Hodgkin Lymphoma


Background: Cytotoxic drugs often suppress the bone marrow’s ability to produce white blood cells which lead to the induction ofneutropenia and the risk of febrile neutropenia. Chemotherapy‑induced neutropenia (CIN) is major dose‑limiting toxicity of systemicchemotherapy and it is associated with significant morbidity and mortality. Objective: Evaluating frequency and severity of CIN afterinitial and subsequent chemotherapy cycles among non‑Hodgkin lymphoma (NHL) children undergoing similar chemotherapy regimens.Patients and Methods: A prospective study performed in the Oncology Department of Child Central Teaching Hospital/Baghdad, betweenAugust 1, 2012, and January 31, 2014, which included (59) patients <15 years, with newly diagnosed NHL who received similar chemotherapyregimens of NHL. All patients were evaluated for the incidence of neutropenia after the initial or subsequent course of chemotherapy tocompare between CIN after first and subsequent chemotherapy cycles of similar regimens, that is,: COPADM1 versus COPADM2 andCOPADM3, “COPADM” regimen includes the following drugs (C: Cyclophosphamide, O: Oncovine, P: Prednisone, AD: Adriamycine, andM: Methotrexate), each chemotherapy cycle was received every 21‑day interval. Results: Of a total 59 patients with NHL,55.9% of them weremale and 44.1% were female, who received initial (COPADM1) and subsequent (COPADM 2 and COPADM 3) chemotherapy cycles of NHL,there is a significant increment in the risk of CIN after initial cycle “COPADM1” in comparison to other subsequent cycles of COPADM2and COPADM3, “P = 0.01.” The patient characteristics (age group and gender) had no significant effect on the risk of CIN, there is a higherpercent of severe neutropenia and hospitalization with parenteral antibiotic use after the first COPADM cycle in comparison with subsequentcycles but statistically not significant (P = 0.6 and 0.1, respectively). Conclusion: Frequency of CIN after the first chemotherapy cycle hadsignificantly higher than subsequent cycles, with lesser extent to neutropenic severity and neutropenia‑related hospitalization.